Patent US4499072A successfully refreshed from Google Patents.
US4499072A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for treating diseases with ODC inhibitors
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1983-01-24
•
Granted: 1985-02-12
•
Expires: 2003-01-24
Abstract
Abstract This invention relates to the improvement of the polyamine depletion effects of ornithine decarboxylase inhibitors and/or S-adenosylmethionine decarboxylase inhibitors, the improvement being effected by the use of interferon in conjunctive therapy with said inhibitors.
Inventors
- 👤 Sai P. Sunkara
- 👤 Nellikunja J. Prakash
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 04:22
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
43 words
In the process of effecting polyamine depletion with ornithine decarboxylase inhibitors and with S-adenosylmethionine decarboxylase inhibitors useful in the treatment of rapidly proliferating tumor tissue disease states the improvement which comprises the use of an effective amount of interferon in conjunctive thereapy therewith.
Claim 2
Dependent Claim
43 words
In the process of effecting polyamine depletion with ornithine decarboxylase inhibitors and with S-adenosylmethionine decarboxylase inhibitors useful in the treatment of rapidly proliferating tumor tissue disease states the improvement which comprises the use of an effective amount of interferon in conjunctive thereapy therewith.
Claim 3
Dependent Claim
15 words
A process of claim 1 wherein the interferon is utilized with an ornithine decarboxylase inhibitor.
Claim 4
Dependent Claim
19 words
A process of claim 2 wherein the ornithine decarboxylase inhibitor is α-difluoromethyl ornithine or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
23 words
A process of claim 2 wherein the ornithine decarboxylase inhibitor is the methyl ester of monofluoromethyl dehydroornithine or a pharmaceutically acceptable salts thereof.
Claim 6
Dependent Claim
23 words
A process of claim 2 wherein the ornithine decarboxylase inhibitor is the R,R-isomer of methyl acetylenic putrescine or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
15 words
A process of claim 1 wherein the interferon is utilized with an S-adenosylmethionine decarboxylase inhibitor.
Claim 8
Dependent Claim
13 words
A processor of claim 6 wherein the S-adenosylmethionine decarboxylase inhibitor is methylglyoxal bis(guanylhydrazone).
Claim 9
Dependent Claim
20 words
A process of claim 1 wherein the interferon is utilized with the conjunctive effects of α-difluoromethyl ornithine and methylglyoxal bis(guanylhydrazone).
Claim 10
Dependent Claim
28 words
A process of claim 1 wherein the polyamine depletion effect is utilized in controlling the growth rate of rapidly proliferating tumor tissue in a patient in need thereof.
Claim 11
Dependent Claim
18 words
A process of claim 9 wherein the ornithine decarboxylase inhibitor is α-difluoromethyl ornithine or pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
22 words
A process of claim 9 wherein the ornithine decarboxylase inhibitor is methyl ester of monofluoromethyl dehydroornithine or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
23 words
A process of claim 9 wherein the ornithine decarboxylase inhibitor is the R,R-isomer of methyl acetylenic putrescine or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
15 words
A process according to claims 2 or 3 wherein the disease state is Malignant Melonoma.
Claim 15
Dependent Claim
16 words
A process according to claims 2 or 3 wherein the disease state is Chronic Myelogenous Leukemia.
Claim 16
Dependent Claim
16 words
A process according to claims 2 or 3 wherein the disease state is Renal Cell Carcinoma.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-02-12 | 1988-08-13 | 1989-02-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-02-12 | 1992-08-13 | 1993-02-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-02-12 | 1996-08-13 | 1997-02-12 | $7700.00 | Window Closed / Lapsed |